Exploring newer cardioprotective strategies: ω-3 fatty acids in perspective

Summary

In the 1980s, observational retrospective studies showed an inverse relation between coronary heart disease (CHD) and consumption of fish containing fatty acids that belong to the omega (ω)-3 family. Large case-control studies and prospective intervention trials consistently showed that ω-3 fatty acids supplementation lowers fatal myocardial infarction (MI) and sudden cardiac death. By analysing the strengths of the results of individual studies and how the meta-analyses agree with them, putting together relevant backgrounds, and identifying open questions, the following findings/directions emerge. (i) Dietary and non-dietary intake of ω-3 fatty acids reduces overall mortality, mortality due to MI, and sudden death in patients with CHD; (ii) Fish oil consumption directly or indirectly affects cardiac electrophysiology. Fish oil reduces heart rate, a major risk factor for sudden death; (iii) Among patients with implantable cardioverter defibrillators, ω-3 fatty acids do not reduce the risk of ventricular tachycardia/ventricular fibrillation and may actually be pro-arrhythmic; (iv) The consumption of ω-3 fatty acids leads to a 10–33% net decrease of triglyceride levels. The effect is dose-dependent, larger in studies with higher mean baseline triglyceride levels, and consistent in different populations (healthy people, people with dyslipidaemia, diabetes, or known cardiovascular risk factors); (v) Outcomes for which a small beneficial effect ω-3 fatty acids is found include blood pressure (about 2 mmHg reduction), re-stenosis rates after coronary angioplasty (14% reduction), and exercise tolerance testing. Major experimental data provide strength (biological plausibility) for these findings, and define directions for newer clinical trials with ω-3 fatty acids.

Keywords

Prevention - acute myocardial infarction - nutrition

• References

• 1 Patel JV, Tracey I, Hughes EA. et al. Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy. Vasc.. Health Risk Manag 2009; 5: 801-810.
• 2 Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease.. N Engl J Med 1985; 312: 1205-1209.
• 3 Shekelle RB, Missell LV, Oglesby P. et al. Fish consumption and mortality from coronary heart disease.. N Engl J Med 1985; 313 (13) 820-4.
• 4 Norell SE, Ahloom A, Feychting M. et al. Fish consumption and mortality from coronary heart disease.. Br Med J 1986; 293: 426.
• 5 Dyerberg J, Bang HO, Stoffersen E. et al. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?. Lancet II 1978; 117-119.
• 6 Albert CM, Hennekens CH, O’Donnell CJ. et al. Fish consumption and risk of sudden cardiac death.. J Am Med Assoc 1998; 279: 23-28.
• 7 Albert CM, Campos H, Stampfer MJ. et al. Blood levels of long-chain ω-3 fatty acids and the risk of sudden death. n-3 fatty acids and the risk of sudden death.. N Engl J Med 2002; 346: 1113-1118.
• 8 Hu FB, Bronner L, Willett WC. et al. Fish and ω-3 fatty acids intake and risk of coronary heart disease in women.. J Am Med Assoc 2002; 287: 1815-1821.
• 9 Oomen CM, Feskens EJ, Räsänen L. et al. Fish consumption and coronary heart disease mortality in Finland, Italy and the Netherlands.. Am J Epidemiol 2000; 151: 999-1006.
• 10 Lemaitre RN, King IB, Mozaffarian D. et al. n-3 polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the Cardiovascular Health Study.. Am J Clin Nutr 2003; 77: 319-325.
• 11 Simon JA, Hodgkins ML, Browner WS. et al. Serum fatty acids and the risk of coronary heart disease.. AmJ Epidemiol 1995; 142: 469-476.
• 12 Burr ML, Gilbert JF, Holliday RM. et al. Effects of changes in fat, fish, and fiber in-takes on death and myocardial infarction : diet and myocardial infarction (DART).. Lancet II 1989; 2: 757-761.
• 13 de Lorgeril M, Renaud S, Mamelle N. et al. Mediterranean alpha-linolenic acid rich diet in secondary prevention of coronary heart disease.. Lancet 1994; 343: 1454-1459.
• 14 Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico (GISSI)-Prevenzione Investigators: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial.. Lancet 1999; 354: 447-455 [published correction: Lancet 2001; 357: 642
• 15 Marchioli R, Barzi F, Bomba E. et al. GISSI-Prevenzione Investigators.. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione.. Circulation. 2002; 105: 1897-1903.
• 16 Macchia A, Levantesi G, Franzosi MG. et al. GISSI Prevenzione Investigators.. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids.. Eur J Heart Fail 2005; 7: 904-909.
• 17 Ness AR, Hughes J, Elwood PC. et al. The long-term effect of dietary advice in men with coronary disease: follow-up of the diet and reinfarction trial (DART).. Eur J Clin Nutr 2002; 56: 512-518.
• 18 Burr ML, Ashfield-Watt PA, Dunstan FD. et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial.. Eur J Clin Nutr 2003; 57: 193-200.
• 19 von Schacky C, Harris WS. Cardiovascular benefits of ω-3 fatty acids.. Cardiovasc Res 2007; 73: 310-315.
• 20 Nilsen DW, Albrektsen G, Landmark K. et al. Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol.. Am J Clin Nutr 2001; 74: 50-56.
• 21 Yokoyama M, Origasa H, Matsuzaki M. et al., for the Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open label, blinded endpoint analysis.. Lancet 2007; 369: 1090-1098.
• 22 FAO/WHO.. Fats and oils in human nutrition report of a joint expert consultation. Food and Agriculture Organization of the United Nations and the World Health Organization.. FAO Food Nutr Pap 1994; 57: 1-147.
• 23 Tavazzi L, Maggioni AP, Marchioli R. et al. Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.. Lancet 2008; 372: 1223-1230.
• 24 Tavazzi L, Maggioni AP, Marchioli R. et al. Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.. Lancet 2008; 372: 1231-1239.
• 25 Siscovick DS, Raghunathan TE, King I. et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest.. J Am Med Assoc 1995; 274: 1363-1367.
• 26 Calo L, Bianconi L, Colivicchi F. et al. N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery (a randomized, controlled trial).. J Am Coll Cardiol 2005; 45: 1723-1728.
• 27 Leaf A, Albert CM, Josephson M. et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake.. Circulation 2005; 112: 2762-2768.
• 28 Raitt MH, Connor WE, Morris C. et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial.. J Am Med Assoc 2005; 293: 2884-2891.
• 29 Brouwer IA, Zock PL, Camm AJ. et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on O-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial.. J Am Med Assoc 2006; 295: 2613-2619.
• 30 Jacobson TA. Beyond Lipids: The Role of ω-3 Fatty Acids from Fish Oil in the prevention of Coronary Heart Disease.. Curr Atheroscl Rep 2007; 9: 145-153.
• 31 Bucher HC, Hengstler P, Schindler C. et al. ω-3 fatty acids polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials.. Am J Med 2002; 112: 298-304.
• 32 Balk E, Chung M, Lichtenstein A. et al. for the Tufts-New England Medical Center Evidence-Based Practice Center, Boston, MA. Effects of omega--3 Fatty Acids On Cardiovascular Risk Factors And Intermediate Markers Of Cardiovascular Disease: Summary, Evidence Report/Technology Assessment No. 93.. Rockville, MD: Agency for Healthcare Research and Quality; March 2004. AHRQ Publication No. 04-E010–2.
• 33 Hooper L, Thompson RL, Harrison RA. et al. omega- 3 fatty acids for prevention and treatment of cardiovascular disease.. Cochrane Database Syst Rev 2004; 4: CD003177.
• 34 He K, Song Y, Daviglus ML. et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies.. Circulation 2004; 109: 2705-2711.
• 35 Studer M, Briel M, Leimenstoll B. et al. Effect of different antilipidemic agents and diets on mortality (a systematic review).. Arch Intern Med 2005; 165: 725-730.
• 36 Mozaffarian D, Geelen A, Brouwer IA. et al. Effect of fish oil on heart rate in humans (a meta-analysis of randomized controlled trials).. Circulation 2005; 112: 1945-1955.
• 37 Hooper L, Thompson RL, Harrison RA. et al. Risks and benefits of ?ω-3 fats for mortality, cardiovascular disease, and cancer: a systematic review.. Br Med J 2006; 332: 752-760.
• 38 MacLean CH, Newberry SJ, Mojica WA. et al. Effects of ω-3 fatty acids on cancer risk: a systematic review.. J Am Med Assoc 2006; 295: 403-415.
• 39 Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits.. J Am Med Assoc 2006; 296: 1885-1899.
• 40 Brouwer IA, Raitt MH, Dullemeijer C. et al. Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators.. Eur Heart J 2009; 30: 820-826.
• 41 Harris WS. ω-3 fatty acids and cardiovascular disease: a case for ω-3 index as a new risk factor.. Pharmacol Res 2007; 55: 217-223.
• 42 Di Minno G, Tufano A, Garofano T, Di Minno MND. Polyunsaturated fatty Acids, thrombosis and vascular disease.. Patophysiol Haemost Thromb 2002; 32: 361-364.
• 43 Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias.. N Engl J Med 2001; 345: 1473-1482.
• 44 Pepe S, McLennan PL. Cardiac membrane fatty acid composition modulates myocardial oxygen consumption and postischemic recovery of contractile function.. Circulation 2002; 105: 2303-2308.
• 45 O’Keefe Jr JH, Abuissa H, Sastre A. et al. Effects of ω-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions.. Am J Cardiol 2006; 97: 1127-1130.
• 46 Abuissa A, O’Keefe Jr JH, Harris WS. et al. Autonomic function, ω-3, and cardiovascular risk.. Chest 2005; 127: 1088-1091.
• 47 Leaf A, Kang JX, Xiao YF. et al. n-3 Fatty acids in the prevention of cardiac arrhythmias.. Lipids 1999; 34 (Suppl) S187-S189.
• 48 Hallaq H, Smith TW, Leaf A. Modulation of dihydropyridine-sensitive calcium channels in heart cells by fish oil fatty acids.. Proc Natl Acad Sci USA 1992; 89: 1760-1764.
• 49 Xiao YF, Ke Q, Wang SY. et al. Single point mutations affect fatty acid block of human myocardial sodium channel alpha subunit Na+ channels.. Proc Natl Acad Sci USA 2001; 98: 3606-3611.
• 50 Anand RG, Alkadri M, Lavie CJ. et al. The role of fish oil in arrhythmia prevention.. J Cardiopulm Rehabil Prev 2008; 28: 2-8.
• 51 Harris WS, Gonzales M, Laney N. et al. Effects of ω-3 fatty acids on heart rate in cardiac transplant recipients.. Am J Cardiol. 2006; Nov 15 98 (10) 1393-1395.
• 52 Cerbone AM, Cirillo F. Coppola a, et al. Persistent impairment of platelet aggregation following cessation of a short course dietary supplementation of moderate amounts of ω-3 fatty acid ethyl esters.. Thromb Haemost 1999; 82: 128-133.
• 53 Gaidiano G, Ghigo D, Schena M. et al. Na+/K+ exchange activation mediates the lipopolysaccharide-induced proliferation of human lymphocytes and is impaired in malignant B-chronic lymphocytic leukemia lymphocyte.. J Immunol 1989; 142: 913-918.
• 54 Resnik LM, Gupta RK, Sosa RE. et al. Intracellular pH in human and experimental hypertension.. Proc Natl Acad Sci USA 1987; 84: 7663-7667.
• 55 Lee JH, O’Keefe JH, Lavie CJ. et al. Ω-3 Fatty Acids for Cardioprotection Mayo Clin.. Proc 2008; 83: 324-332.
• 56 Ventura HO, Milani RV, Lavie CJ. et al. Cyclosporine-induced hypertension: efficacy of ?--3 fatty acids in patients after cardiac transplantation.. Circulation 1993; 88: II281-II285.
• 57 Thies F, Garry JM, Yaqoob P. et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial.. Lancet 2003; 361: 477-485.
• 58 Geleijnse JM, Giltay EJ, Grobbee DE. et al. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials.. J Hypertens 2002; 20: 1493-1499.
• 59 Ueshima H, Stamler J, Elliott P. et al, INTERMAP Research Group. Food ω-3 fatty acid intake of individuals (total, linolenic acid, long-chain) and their blood pressure: INTERMAP study.. Hypertension 2007; 50: 313-319.
• 60 Wada M, Delong CJ, Hong YH. et al. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid derived substrates and products.. J Biol Chem 2007; 282: 22254-22266.
• 61 Itoh M, Suganami T, Satoh N. et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects.. Arterioscler Thromb Vasc Biol 2007; 27: 1918-1925.
• 62 Mehra MR, Lavie CJ, Ventura HO. et al. Fish oils produce antiinflammatory effects and improve body weight in severe heart failure.. J Heart Lung Transplant 2006; 25: 834-838.
• 63 Din JN, Harding SA, Valerio CJ. et al. Dietary intervention with oil rich fish reduces platelet-monocyte aggregation in man.. Atherosclerosis. 2007 prepub online doi: 10.1016/j.atherosclerosis.2007.04. 047.
• 64 Schmidt EB, Pedersen JO, Varming K. et al. n-3 fatty acids and leukocyte chemo-taxis: effects in hyperlipidemia and dose-response studies in healthy men.. Arterioscler Thromb 1991; 11: 429-435.
• 65 Calder PC. Polyunsaturated fatty acids and inflammation.. Prostaglandins Leukot Essent Fatty Acids 2006; 75: 197-202.
• 66 Shi Y, Zhang P, Zhang L. et al. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses.. Atherosclerosis 2007; 191: 54-62.
• 67 Zhao G, Etherton TD, Martin KR. et al. Dietary α-linolenic acid inhibits proinflammatory cytokine production by peripheral blood mononuclear cells in hypercholesterolemic subjects.. Am J Clin Nutr 2007; 85: 385-391.
• 68 He K, Liu K, Daviglus ML. et al. Associations of dietary long-chain n-3 polyunsaturated fatty acids and fish with biomarkers of inflammation and endothelial activation (from the Multi-Ethnic Study of Atherosclerosis [MESA]).. Am J Cardiol 2009; 103: 1238-1243.
• 69 Madsen T, Schmidt EB, Christensen JH. The effect of n-3 fatty acids on C-reactive protein levels in patients with chronic renal failure.. J Ren Nutr 2007; 17: 258-263.
• 70 Lee KW, Blann AD, Lip GY. Effects of omega-3 polyunsaturated fatty acids on plasma indices of thrombogenesis and inflammation in patients post-myocardial infarction.. Thromb Res 2006; 118: 305-312.
• 71 Hansen J, Grimsgaard S, Nordoy A. et al. Dietary supplementation with highly purified eicosapentaenoic acid and docosahexaenoic acid does not influence PAI-1 activity.. Thromb Res 2000; 98: 123-132.
• 72 Davidson MH, Stein EA, Bayes HE. et al. COMBination of prescription Ω-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription ω-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo controlled study.. Clin Ther 2007; 29: 1354-1367.
• 73 Harris WS. n-3 fatty acids and serum lipoproteins: human studies.. Am J Clin Nutr 1997; 65 (05) 1645s-1654s.
• 74 Harris WS, Ginsberg HN, Arunakul N. et al. Safety and efficacy of Omacor in severe hypertriglyceridemia.. J Cardiovas Risk 1997; 4: 385-391.
• 75 Pedersen MW, Koenig W, Christensen JH. et al. The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults.. Eur J Nutr 2009; 48: 1-5.
• 76 Thies F, Garry JM, Yaqoob P. et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial.. Lancet 2003; 361: 477-485.
• 77 Weintraub HS. Identifying the vulnerable patient with rupture-prone plaque.. Am J Cardiol 2008; 101: 3F-10F.
• 78 Miller M. Is hypertriglyceridaemia an independent risk factor for coronary heart disease?. Eur Heart J 1998; 19: H18-H22.
• 79 Manninen V, Tenkanen L, Koskinen P. et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.. Circulation 1992; 85: 37-45.
• 80 Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta analysis of population-based prospective studies.. J Cardiovasc Risk 1996; 3: 213-299.
• 81 Nordestgaard BG, Benn M, Schnohr P. et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.. J Am Med Assoc 2007; 298: 299-308.
• 82 British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association.. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice.. Heart 2005; 91 (05) v1-v5.
• 83 Rubins HB, Robins SJ, Collins D. et al. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.. N Engl J Med 1999; 341: 410-418.
• 84 The BIP Study Group.. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study.. Circulation 2000; 102: 21-27.
• 85 Meade T, Zuhrie R, Cook C. et al. MRC General Practice Research Framework, Bezafibrate in men with lower extremity arterial disease: randomised controlled trial.. Br Med J 2002; 325: 1139-1141.
• 86 Keech A, Simes RJ, Barter P. et al FIELD study investigators.. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.. Lancet 2005; 366: 1849-1861.
• 87 Stampfer MJ, Krauss RM, Ma J. et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction.. J Am Med Assoc 1996; 276: 882-888.
• 88 Jeppesen J, Hein MO, Suadicani P. et al. Triglyceride concentration and ischaemic heart disease. An eight-year follow-up in the Copenhagen male study.. Circulation 1998; 97: 1029-1036.
• 89 Crepaldi G. Origin and development of the Metabolic Syndrome.. In: The Metabolic Syndrome at the beginning of the XXIst century. A genetic and molecular approach.. Elsevier; Madrid: 2005. pp. 5-12.
• 90 Martín de Santa Olalla L, Sánchez Muniz FJ, Vaquero MP. N-3 fatty acids in glucose metabolism and insulin sensitivity.. Nutr Hosp 2009; 24: 113-127.
• 91 Sirtori CR, Paoletti R, Mancini M. et al. N-3 fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance. Italian Fish Oil Multicenter Study.. Am J Clin Nutr 1997; 65: 1874-1881.
• 92 Ramel A, Martinéz A, Kiely M. et al. Beneficial effects of long-chain n-3 fatty acids included in an energyrestricted diet on insulin resistance in overweight and obese European young adults.. Diabetologia 2008; 51: 1261-1268.
• 93 Tarantino G, Saldalamacchia G, Conca P. et al. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome.. J Gastroenterol Hepatol 2007; 22: 293-303.
• 94 Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD).. Ann Hepatol 2009; 8 (01) S4-8.
• 95 Hamaguchi M, Kojima T, Takeda N. et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.. World J Gastroenterol 2007; 10: 1579-1584.
• 96 Choi SY, Kim D, Kim HJ. et al. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans.. Am J Gastroenterol 2009; 104: 1953-1960.
• 97 Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids – a promising novel therapy for non-alcoholic fatty liver disease.. Aliment Pharmacol Ther 2010; 31: 679-692.
• 98 Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischemia and arrhythmias.. Lancet 1994; 343: 155-158.
• 99 Ommen SR, Odell KA, Stanton MS. Atrial arrythmias after cardiothoracic surgery.. N Engl J Med 1997; 336: 1429-1434.
• 100 Billman GE, Kang JX, Leaf A. Prevention of sudden cardiac death by dietary pure omega-3 polyunsaturated fatty acids in dogs.. Circulation 1999; 99: 2452-2457.
• 101 Breslow JL. ω-3 fatty acids and cardiovascular disease.. Am J Clin Nutr 2006; 83 (Suppl) 1477S-1482S.